Q2 FY2026 · ended Jun 30, 2026 · Revenue $41.92M, +6.1% YoY · Filed Aug 13, 2026
Marimed Inc. (MRMD) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $41.9 million and a net loss of $3.6 million. Free cash flow was $1.9 million. As of Jun 30, 2026 it held $8.4 million in cash and investments and $94.5 million in total debt.
Revenue
$41.92M
+6.1% vs year-ago quarter
Net income
$-3.59M
-157.5% vs year-ago quarter
Operating cash flow
$2.22M
+647.1% vs year-ago quarter
Free cash flow
$1.92M
+16108.3% vs year-ago quarter
EPS
$-0.01
Dividend per share
None
Shares outstanding
403.04M
+2.7% vs year-ago quarter
Net cash
$-86.10M
Q2 FY2026
Operating margin
-1.5%
TTM
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- MRMD (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Norwood, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1522767
- Former names
- WORLDS ONLINE INC. (until May 15, 2017)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $41.9M | $39.5M | $41.6M | $40.8M | $39.5M |
| Operating income | $418,000 | $125,000 | -$4.5M | $1.6M | $1.0M |
| Net income | -$3.6M | -$3.8M | -$4.6M | -$2.9M | -$1.4M |
| Diluted EPS | -$0.01 | -$0.01 | -$0.01 | -$0.01 | $0.00 |
| Operating cash flow | $2.2M | $949,000 | $3.4M | $2.7M | $297,000 |
| Free cash flow | $1.9M | $576,000 | $3.4M | $2.1M | -$12,000 |
| Total assets | $197.2M | $201.2M | $202.6M | $205.6M | $204.4M |
| Total liabilities | $147.1M | $147.7M | $137.8M | $136.6M | $131.2M |
| Stockholders' equity | $43.2M | $46.5M | $50.0M | $54.3M | $56.9M |
| Cash and investments | $8.4M | $7.9M | $8.9M | $6.6M | $6.1M |
| Total debt | $94.5M | $94.4M | $88.7M | $89.4M | $90.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results, Other events
|
Oct 29, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Other events
|
Sep 23, 2026 | Sep 23, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 8, 2026 | Jun 4, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
All 377 Marimed Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.